image: The session moderated by Associate Professor Liu Nan, Director of Duke-NUS Al+ Medical Sciences Initiative (DAlSl) explores the critical aspects of conducting trials for artificial intelligence (Al) technologies.
Credit: Insilico Medicine
From July 30-31, Alex Zhavoronkov, PhD, founder and co-CEO of clinical stage artificial intelligence (AI)-driven drug discovery company Insilico Medicine will be attending SCRI Clinical Trials Symposium 2024 at Raffles City Convention Centre, and Brainstorm AI 2024: The New Race for AI at The Ritz-Carlton, Millenia Singapore, sharing strategic insights with global leaders across the technology and healthcare industries.
On 2:00 p.m, July 31, Alex Zhavoronkov PhD will be speaking at the session named “Methodologies and Considerations for Trials Involving Al-Driven Technologies”, where he is joined by Ms. Karla Childers, the Head of Bioethics-based Science & Technology Policy at Johnson & Johnson, and Associate Professor Tan Cher Heng from Nanyang Technological University (NTU). The session moderated by Associate Professor Liu Nan, Director of Duke-NUS Al+ Medical Sciences Initiative (DAlSl) explores the critical aspects of conducting trials for artificial intelligence (Al) technologies.
Organized by the Singapore Clinical Research Institute (SCRI) with the theme of “The Promise of Clinical Trials: Transforming Tomorrow’s Health”, the grand gathering brings together clinicians, researchers, academics, and industry experts in clinical research from around the world, showcasing the value proposition of clinical trials in Singapore, while providing integrated access to trial information for multiple parties engaged.
On 3:10 p.m, July 30, Alex Zhavoronkov PhD will talk under the title “Will AI make death optional” with Christine Yuan Huang, Founder and CEO of Quantum Life, and Jeremy Kahn from Fortune magazine. Topics including AI advancements in longevity research, AI-accelerated drug discovery, and aging prediction are likely to be discussed.
In 2024, the inaugural gathering of Brainstorm AI in Singapore bring together the top minds across Asia from the Fortune Global 500, Fortune Europe 500 and Fortune 500 lists, investors, policymakers, and academics to explore the profound impacts of AI on business, society, and the global order.
Alex Zhavoronkov, PhD, a Clarivate Highly Cited Researcher, is the founder and CEO of Insilico Medicine, which raised over $300 million in multiple rounds from expert investors and spread its business across four continents under his leadership. Since 2012, he has published over 200 peer-reviewed research papers, and 2 books.
Founded in 2014, Insilico Medicine is a pioneer in using generative AI for drug discovery and development. Insilico first described the concept of using generative AI for the design of novel molecules in a peer-reviewed journal in 2016, which laid the foundation for the commercially available Pharma.AI platform spanning across biology, chemistry and clinical development. Powered by Pharma.AI, Insilico has nominated 18 preclinical candidates in its comprehensive portfolio of over 30 assets since 2021 and has received IND approval for 7 molecules. Recently, the company published a paper in Nature Biotechnology presenting the entire R&D journey of its lead drug pipeline, INS018_055, from AI algorithms to Phase II clinical trials.
About Insilico Medicine
Insilico Medicine, a global clinical stage biotechnology company powered by generative AI, is connecting biology, chemistry and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases.
www.insilico.com